Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025

Description

Human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is a form of stomach or gastroesophageal junction cancer characterized by an overexpression of the HER2 protein or amplification of the HER2 gene, which drives cancer cell growth. This subtype is responsive to specific targeted therapies, leading to improved outcomes for suitable patients.

The primary treatment options for HER2-positive gastric cancer include chemotherapy, immunotherapy, radiation therapy, and targeted therapy. Chemotherapy involves the use of potent drugs that circulate through the bloodstream to kill rapidly dividing cancer cells, including those in HER2-positive gastric cancer. It is applied across different cancer stages, such as stage I through stage IV, and is utilized by various healthcare providers including ambulatory surgery centers, hospitals, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report is one of a series of new reports from The Business Research Company that provides human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market statistics, including human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry global market size, regional shares, competitors with a human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market share, detailed human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer industry. This human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size has grown steadily in recent years. It will grow from $1.25 billion in 2024 to $1.31 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. Growth during the historic period was driven by the increased use of companion diagnostics, greater awareness among oncologists regarding HER2 biomarkers, a stronger emphasis on personalized cancer treatments, growing interest in antibody-drug conjugates, and enhanced reimbursement policies for targeted therapies.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 4.6%. Growth in the forecast period is expected to result from the expanding availability of molecular diagnostic laboratories, increased awareness campaigns for gastric cancer screening, rising use of next-generation sequencing (NGS), growing demand for outpatient cancer care services, and more global regulatory approvals of HER2-targeted drugs. Key trends during this period include optimizing treatment sequencing, applying nanotechnology in drug delivery, utilizing artificial intelligence in HER2 diagnostics, enhancing antibody-dependent cellular cytotoxicity, and advancing immunotherapy combination approaches.

The increasing use of targeted cancer therapy is expected to drive growth in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market. Targeted therapy, often referred to as personalized medicine, involves treatments that block cancer growth by focusing on specific molecules involved in tumor development. This approach has gained traction due to advancements in genetic profiling, which make it possible to tailor treatments to the individual characteristics of a patient's tumor. In the case of HER2-positive gastric cancer, targeted therapies specifically attack the HER2 protein, which is overexpressed in these tumors, helping to slow disease progression and improve patient outcomes. For example, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023. These included seven cancer drugs and three others for various conditions, up from six in 2022. This trend supports the growing role of targeted therapies in cancer treatment and their contribution to the expansion of the HER2-positive gastric cancer market.

Companies in the HER2-positive gastric cancer space are also prioritizing regulatory approvals for new therapies, particularly combination treatments that integrate immunotherapy, targeted therapy, and chemotherapy. These advanced regimens aim to improve patient outcomes in first-line treatment scenarios by using immune checkpoint inhibitors to block PD-1 or PD-L1 pathways while concurrently targeting HER2 receptors and applying chemotherapeutic agents. This approach enhances anti-tumor activity and improves survival rates. In March 2025, Merck & Co., Inc., a U.S.-based biopharmaceutical company, received FDA approval for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy. This treatment is approved for adults with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1. Clinical results showed this combination significantly improved median progression-free survival and overall survival, with a response rate of 73% and a longer median duration of response. The approval marks a major advancement in managing advanced HER2-positive gastric cancer.

In December 2023, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Seagen Inc. to enhance its portfolio of oncology therapies. This acquisition was intended to strengthen Pfizer's capabilities in the development and delivery of targeted cancer treatments. Seagen Inc. is a U.S.-based biotechnology company known for its specialization in therapies for HER2-positive gastric cancer.

Major players in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor receptor 2 (HER2)-positive gastric cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market consists of sales of trastuzumab, pertuzumab, margetuximab, and lapatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human epidermal growth factor receptor 2 (her2)-positive gastric cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human epidermal growth factor receptor 2 (her2)-positive gastric cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Targeted Therapy
2) By Stage: Stage I; Stage II; Stage III; Stage IV
3) By End-User: Ambulatory Surgery Centers; Hospitals And Specialty Clinics; Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines; Platinum-Based Agents; Taxanes; Irinotecan; Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors; Monoclonal Antibodies; Cancer Vaccines; Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy; Intensity-Modulated Radiation Therapy; Stereotactic Body Radiation Therapy; 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies; Tyrosine Kinase Inhibitors; Antibody-Drug Conjugates; mTOR Inhibitors; PI3K/AKT/mTOR Pathway Inhibitors
Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; Bayer Aktiengesellschaft; Eli Lilly and Company; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Amgen Inc.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Genentech Inc.; Ono Pharmaceutical Co Ltd.; Shanghai Henlius Biotech Inc.; MacroGenics Inc.; Hutchison Medipharma Limited ; ALX Oncology Holdings Inc.; Taiho Pharmaceutical Co Ltd.; Ambrx Biopharma Inc.; LintonPharm Co Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37016

1. Executive Summary

2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Characteristics

3. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Trends And Strategies

4. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Growth Rate Analysis
5.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Total Addressable Market (TAM)

6. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segmentation

6.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Radiation Therapy
Targeted Therapy
6.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stage I
Stage II
Stage III
Stage IV
6.3. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambulatory Surgery Centers
Hospitals And Specialty Clinics
Other End-Users
6.4. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Fluoropyrimidines
Platinum-Based Agents
Taxanes
Irinotecan
Anthracyclines
6.5. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Monoclonal Antibodies
Cancer Vaccines
Cytokine-Based Therapies
6.6. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy
Intensity-Modulated Radiation Therapy
Stereotactic Body Radiation Therapy
3D Conformal Radiation Therapy
6.7. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HER2-Targeted Therapies
Tyrosine Kinase Inhibitors
Antibody-Drug Conjugates
mTOR Inhibitors
PI3K/AKT/mTOR Pathway Inhibitors

7. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Regional And Country Analysis

7.1. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

8.1. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

9.1. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
9.2. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

10.1. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

11.1. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
11.2. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

12.1. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

13.1. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

14.1. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
14.2. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

15.1. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
15.2. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

16.1. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

17.1. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

18.1. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

19.1. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

20.1. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

21.1. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
21.2. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

22.1. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

23.1. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
23.2. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

24.1. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
24.2. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

25.1. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
25.2. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

26.1. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
26.2. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

27.1. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

28.1. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
28.2. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

29.1. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Overview
29.2. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape And Company Profiles

30.1. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Landscape
30.2. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer Aktiengesellschaft Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. Novartis AG
31.4. Amgen Inc.
31.5. Astellas Pharma Inc.
31.6. Daiichi Sankyo Company Limited
31.7. Genentech Inc.
31.8. Ono Pharmaceutical Co Ltd.
31.9. Shanghai Henlius Biotech Inc.
31.10. MacroGenics Inc.
31.11. Hutchison Medipharma Limited
31.12. ALX Oncology Holdings Inc.
31.13. Taiho Pharmaceutical Co Ltd.
31.14. Ambrx Biopharma Inc.
31.15. LintonPharm Co Ltd.

32. Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

34. Recent Developments In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

35. Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market High Potential Countries, Segments and Strategies

35.1 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer